Related Experiment Videos
The cancer/testis genes: review, standardization, and commentary
Matthew J Scanlan1, Andrew J G Simpson, Lloyd J Old
1Ludwig Institute for Cancer Research, New York Branch of Human Cancer Immunology at Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA. scanlanm@mskcc.org
Cancer Immunity
|January 24, 2004
Summary
Cancer/testis (CT) antigens show promise for cancer vaccines due to their immunogenicity and restricted expression. A CT gene database standardizes nomenclature and data on expression, immunogenicity, and function.
Area of Science:
- Immunology
- Genetics
- Oncology
Background:
- Cancer/testis (CT) antigens are immunogenic targets for cancer vaccines.
- 44 CT gene families identified with varied expression across cancer types.
- CT antigens exhibit tissue-restricted expression, crucial for targeted therapies.
Purpose of the Study:
- To consolidate and standardize data on CT genes.
- To analyze expression profiles and immunogenicity of CT antigens.
- To provide a comprehensive resource for cancer vaccine development.
Main Methods:
- RT-PCR used to examine CT transcript expression in various cancers and normal tissues.
- Analysis of expression frequency in high, moderate, and low CT gene expressor cancers.
- Data compilation for CT gene nomenclature, expression, immunogenicity, and function.
Main Results:
- Bladder, lung, and melanoma are high CT expressors; breast and prostate are moderate; renal and colon are low.
- 19/43 CT genes are testis-restricted; others show varying degrees of tissue restriction or ubiquitous expression.
- 14/29 testis/tissue-restricted CT gene families induce immune responses in humans.
Conclusions:
- CT antigens represent viable targets for cancer vaccine development.
- A comprehensive CT gene database aids research and standardization.
- Understanding CT gene expression and immunogenicity is key to advancing cancer immunotherapy.